Modus Therapeutics Holding AB provided an update on its ongoing Phase 1b LPS-challenge study and its other clinical activities with sevuparin. Modus has observed that the ongoing effects of the Covid-19 pandemic throughout spring have slowed down enrolment for the Phase 1b trial, causing a delay to the anticipated timelines. This is largely attributed to subjects being unable to take part if they have contracted Covid-19 or have had a Covid vaccination within the screening/enrolment period.

The company now expects to finalize recruitment by end third quarter. Due to the delay caused by external circumstances mainly relating to the pandemic and outside of company control, the previously announced interim analysis cannot be performed within the anticipated timelines and is therefore cancelled. Modus is now focused on improving the pace of recruitment into the trial and has taken several initiatives to ensure acceleration for full enrollment.

These include updates to the selection criteria which now allows the enrolment of female subjects into the study.